Milmed treatment alleviates symptoms of allergy and improves general health

The effects of the patented treated-yeast, Saccharomyces cerevisiae, a probiotic suspension which was shown earlier to present neuroprotective and neurorestorative properties, upon allergies presented by a group (n=8) of patients, that were compared with a matched group of patients administered untreated yeast cells (n=8). Treated yeast cells were subjected to millimeter-wave exposure as outlined in patented documents. The patients who administered themselves treated Milmed, over periods extending from four-tothirteen weeks, completed subjective self-report ratings of their allergy symptoms that indicated marked ameliorative effects; additionally, they rated their general health situations to be markedly improved. Those patients who had taken the untreated yeast did not report these improvements. Correlational analyses between the number of weeks treated Milmed was taken by patients and (i) alleviation of allergy symptoms, and (ii) improvement in general health status, indicated significant relationships in each case. The significant correlations between symptom improvements and general health status, on one hand, and the number of weeks treated Milmed was ingested imply that complete treatments are required for the optimal therapeutic benefits. As observed previously, 8-to-13-week episodes of treated Milmed self-administration provides a lasting amelioration from allergy symptoms and an improved general health status.